Ann: AGM Presentation, page-4

Thanks for sharing your take of the meeting, kiwig. 33% more accurate than a FIT test is a number that just blows the competition off the track. Good to see they are sticking to their call of having CE Mark approval in the next 5 weeks, but seeing they seemingly have not even applied yet would suggest that they are cutting it fine and that may be a milestone that drift into calendar 2022.

To be clear, the market that they are currently moving into is a $38b one so commercial success in that alone could transform ColoSTAT into a blockbuster product. Were they to indicate in the near term that they have identified other cancers they can target then then we'd start talking about real money. From a totally non-science point of view it would be great that they could do something about the early identification of pancreatic cancer which is an absolute beast. Anyone out there with a medical / scientific background who can suggest what cancer types the company is likely to be investigating?